Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS.
Salomon-Zimri S, Pushett A, Russek-Blum N, Van Eijk RPA, Birman N, Abramovich B, Eitan E, Elgrart K, Beaulieu D, Ennist DL, Berry JD, Paganoni S, Shefner JM, Drory VE. Salomon-Zimri S, et al. Among authors: van eijk rpa. Amyotroph Lateral Scler Frontotemporal Degener. 2023 May;24(3-4):263-271. doi: 10.1080/21678421.2022.2119868. Epub 2022 Sep 15. Amyotroph Lateral Scler Frontotemporal Degener. 2023. PMID: 36106817 Clinical Trial.
Loss of appetite is associated with a loss of weight and fat mass in patients with amyotrophic lateral sclerosis.
Ngo ST, van Eijk RPA, Chachay V, van den Berg LH, McCombe PA, Henderson RD, Steyn FJ. Ngo ST, et al. Among authors: van eijk rpa, van den berg lh. Amyotroph Lateral Scler Frontotemporal Degener. 2019 Nov;20(7-8):497-505. doi: 10.1080/21678421.2019.1621346. Epub 2019 May 30. Amyotroph Lateral Scler Frontotemporal Degener. 2019. PMID: 31144522
Implications of spirometric reference values for amyotrophic lateral sclerosis.
van Eijk RPA, Bakers JNE, van Es MA, Eijkemans MJC, van den Berg LH. van Eijk RPA, et al. Among authors: van es ma, van den berg lh. Amyotroph Lateral Scler Frontotemporal Degener. 2019 Nov;20(7-8):473-480. doi: 10.1080/21678421.2019.1634736. Epub 2019 Jul 4. Amyotroph Lateral Scler Frontotemporal Degener. 2019. PMID: 31271047
In pursuit of the normal progressor: the holy grail for ALS clinical trial design?
van Eijk RPA, van Den Berg LH. van Eijk RPA, et al. Among authors: van den berg lh. Amyotroph Lateral Scler Frontotemporal Degener. 2020 Feb;21(1-2):1-2. doi: 10.1080/21678421.2019.1675710. Epub 2019 Oct 11. Amyotroph Lateral Scler Frontotemporal Degener. 2020. PMID: 31603357 No abstract available.
A placebo-controlled trial to investigate the safety and efficacy of Penicillin G/Hydrocortisone in patients with ALS (PHALS trial).
Van Es MA, Van Eijk RPA, Bunte TM, Van Den Berg LH. Van Es MA, et al. Among authors: van eijk rpa, van den berg lh. Amyotroph Lateral Scler Frontotemporal Degener. 2020 Nov;21(7-8):584-592. doi: 10.1080/21678421.2020.1788093. Epub 2020 Jul 6. Amyotroph Lateral Scler Frontotemporal Degener. 2020. PMID: 32627599 Clinical Trial.
An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials.
van Eijk RPA, de Jongh AD, Nikolakopoulos S, McDermott CJ, Eijkemans MJC, Roes KCB, van den Berg LH. van Eijk RPA, et al. Among authors: van den berg lh. Amyotroph Lateral Scler Frontotemporal Degener. 2021 May;22(3-4):300-307. doi: 10.1080/21678421.2021.1879865. Epub 2021 Feb 2. Amyotroph Lateral Scler Frontotemporal Degener. 2021. PMID: 33527843 Free article.
Using the ALSFRS-R in multicentre clinical trials for amyotrophic lateral sclerosis: potential limitations in current standard operating procedures.
Bakers JNE, de Jongh AD, Bunte TM, Kendall L, Han SS, Epstein N, Lavrov A, Beelen A, Visser-Meily JMA, van den Berg LH, van Eijk RPA. Bakers JNE, et al. Among authors: van eijk rpa, van den berg lh. Amyotroph Lateral Scler Frontotemporal Degener. 2022 Nov;23(7-8):500-507. doi: 10.1080/21678421.2021.2016838. Epub 2021 Dec 24. Amyotroph Lateral Scler Frontotemporal Degener. 2022. PMID: 34949141
Clinical trials in pediatric ALS: a TRICALS feasibility study.
Kliest T, Van Eijk RPA, Al-Chalabi A, Albanese A, Andersen PM, Amador MDM, BrÅthen G, Brunaud-Danel V, Brylev L, Camu W, De Carvalho M, Cereda C, Cetin H, Chaverri D, Chiò A, Corcia P, Couratier P, De Marchi F, Desnuelle C, Van Es MA, Esteban J, Filosto M, GarcÍa Redondo A, Grosskreutz J, Hanemann CO, HolmØy T, HØyer H, Ingre C, Koritnik B, Kuzma-Kozakiewicz M, Lambert T, Leigh PN, Lunetta C, Mandrioli J, Mcdermott CJ, Meyer T, Mora JS, Petri S, Povedano M, Reviers E, Riva N, Roes KCB, Rubio MÁ, Salachas F, Sarafov S, SorarÙ G, Stevic Z, Svenstrup K, MØller AT, Turner MR, Van Damme P, Van Leeuwen LAG, Varona L, VÁzquez Costa JF, Weber M, Hardiman O, Van Den Berg LH. Kliest T, et al. Among authors: van es ma, van eijk rpa, van leeuwen lag, van damme p, van den berg lh. Amyotroph Lateral Scler Frontotemporal Degener. 2022 Nov;23(7-8):481-488. doi: 10.1080/21678421.2021.2024856. Epub 2022 Feb 16. Amyotroph Lateral Scler Frontotemporal Degener. 2022. PMID: 35172656 Free PMC article.
105 results